(18 Mar 2021) Favipiravir- was more effective than LPV/RTV in reducing mortality

The Comparison of Lopinavir/Ritonavir Combination and Favipiravir In COVID-19 Treatment

https://doi.org/10.3906/sag-2012-189

Of the 204 patients with COVID-19 pneumonia, 59 (28.9%), 131 (64.2%), and 14 were administered LPV/RTV, favipiravir, and favipiravir with LPV/RTV, respectively. No difference was found in age, sex, presence of comorbidity, and tocilizumab, systemic corticosteroid, and plasma therapy use between patients administered with these three different treatment regimens. The mean mortality age of the patients was 71+/-14.3 years, which was substantially greater than that of the survivors (54.2+/-15.5 years). Compared with patients administered with LPV/RTV, ICU admission and mortality rates were lower in patients administered with favipiravir. CK-MB, AST, CRP, LDH, and creatinine levels were higher, whereas lymphocyte counts were lower in patients who died. Age, AST, CRP, LDH, and neutrophil counts were higher in patients needing ICU, and eosinophil and lymphocyte counts were significantly lower. Logistic regression analysis showed that favipiravir use independently decreased mortality (P=0.006). The use of favipiravir was more effective than LPV/RTV in reducing mortality in hospitalized patients with COVID-19.